Nirvana Life Sciences Inc. is a Canada-based biotechnology company focused on the research and development of therapeutic products derived from psychedelics to address addiction and pain management. Operating in a single reportable segment, it develops novel formulations of psilocybin and other naturally sourced psychedelics, including methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The company has prioritized two initial products: a one-per-day slow-release gel cap designed to assist the transition from opioids to non-addictive pain relief therapies, and another one-per-day slow-release gel cap providing non-addictive pain relief. These formulations support a range of therapeutic medicines and products. Nirvana Life Sciences Inc. also cultivates several genera and species of fungi, including rare and hybrid varieties, emphasizing quality and batch consistency. Headquartered in Vancouver, Canada, it targets the biotechnology and medical research sector, contributing to innovative treatments for opioid dependency and related health challenges.